H. Lee Moffitt Cancer Center & Research Institute to Hold Symposium: 'Beyond Chemotherapy: Are Prevention and Cure in Sight?' 2/25/2003
From: Andrea Brunais of the H. Lee Moffitt Cancer Center & Research Institute, 813-632-1478; E-mail: mediarelations@moffitt.usf.edu News Advisory: "Beyond Chemotherapy: Are Prevention and Cure in Sight?" Symposium for Journalists at the H. Lee Moffitt Cancer Center & Research Institute, Tampa Fla. will be Webcast Feb. 26, 2 p.m. - 6 p.m. The Webcast requires Windows Media Player. Top doctors and researchers discuss the latest in theory, treatment and science. Developing and testing the tumor vaccine. How today's drug creation looks for drugs that kill only the cancer, not the healthy cells. And advances in gene profiling for cancer diagnosis and treatment. Go to: http://www.MoffittCancerNetwork.org Seminar presenters: Jack Pledger, Ph.D. Deputy Director of Moffitt Cancer Center and chief of Basic Research, Dr. Pledger has played an invaluable role in assembling Moffitt's Basic Science Program research team and initiating genetic immunotherapy research. Moffitt's first Scientist of the Year in 2001. Edwardo Sotomayor, M.D. Having trained in Immunology and Internal Medicine at the University of Miami School of Medicine/Jackson Memorial Hospital in Miami, FL, and in Hematology/Oncology at The Johns Hopkins Cancer Center in Baltimore, MD, Dr. Sotomayor is working on vaccines that can induce a patient's own immune system to destroy lymphoma tumors. Said Sebti, Ph.D. Dr. Sebti has produced benchmark research showing that a member of a family of anticancer drugs called farnesyltransferase could be a viable cancer therapeutic. The Director of the Drug Discovery Program at Moffitt, Dr. Sebti has authored more than 140 research articles. Rebecca Sutphen, M.D. A clinical geneticist, Dr. Sutphen is the principal investigator for two studies, both of which are designed to investigate the connection between genetics and cancer. The first study looks at women with newly diagnosed ovarian cancer. Timothy Yeatman, M.D. Leader of Moffitt's Gastrointestinal Tumor Program, Dr. Yeatman is researching gene expression profiling under a $6 million National Institutes of Health Director's Challenge Grant. In 2001 the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the Top 10 cancer hospitals in America. Moffitt's sole mission is to contribute to the prevention and cure of cancer. ------ Information: Andrea Brunais in Media Relations (813) 632-1478 or e-mail mediarelations@moffitt.usf.edu |